Accepted Manuscript

Title: Cardiovascular risk factors in patients with Spondyloarthritis from Northern European and Mediterranean countries: an ancillary study of the ASAS-COMOSPA project

Authors: Clementina López-Medina Yolanda Jiménez-Gómez Anna Moltó Ruxandra Elena Schiotis Helena Marzo-Ortega Floris A. van Gaalen Salih Ozgocmen Maxime Dougados Jerusalem Calvo-Gutiérrez M. Carmen Castro-Villegas Eduardo Collantes-Estévez Pilar Font-Ugalde, on behalf of the ASAS-COMOSPA task force

PII: S1297-319X(17)30139-2
Reference: BONSOI 4620

To appear in:

Received date: 18-5-2017
Accepted date: 12-7-2017


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Cardiovascular risk factors in patients with Spondyloarthritis from Northern European and Mediterranean countries: an ancillary study of the ASAS-COMOSPA project

Clementina López-Medina\textsuperscript{a,b,c,*}, Yolanda Jiménez-Gómez\textsuperscript{a,b,c,*}, Anna Moltó\textsuperscript{d,e}, Ruxandra Elena Schiotis\textsuperscript{f}, Helena Marzo-Ortega\textsuperscript{g}, Floris A. van Gaalen\textsuperscript{h}, Salih Ozgocmen\textsuperscript{i}, Maxime Dougados\textsuperscript{d,e}, Jerusalem Calvo-Gutiérrez\textsuperscript{a,b,c}, M. Carmen Castro-Villegas\textsuperscript{a,b,c}, Eduardo Collantes-Estévez\textsuperscript{a,b,c}, Pilar Font-Ugalde\textsuperscript{a,b,c}, on behalf of the ASAS-COMOSPA task force\textsuperscript{**}. 

\textsuperscript{a}Maimónides Institute for Research in Biomedicine of Córdoba (IMIBIC), 14004 Córdoba, Spain.
\textsuperscript{b}Rheumatology Department, Reina Sofia University Hospital, 14004 Córdoba, Spain.
\textsuperscript{c}Córdoba University (UCO), 14004 Córdoba, Spain.
\textsuperscript{d}Paris Descartes University, Rheumatology Department, Cochin Hospital, AP-HP, 75014 Paris, France.
\textsuperscript{e}INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, 75014 Paris, France.
\textsuperscript{f}Iuliu Hatieganu, University of Medicine and Pharmacy and Department of Rheumatology, SCBI, 400012 Cluj-Napoca, Romania.
\textsuperscript{g}Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Alberton Hospital, LS7 4SA Leeds, UK.
\textsuperscript{h}Leiden University Medical Center, 2333 ZA Leiden, The Netherlands. \textsuperscript{i}Department of Rheumatology, Medicalpark Gaziosmanpasa, 34250 Istambul, Turkey.
CORRESPONDING AUTHOR:

Clementina López-Medina. Reina Sofia University Hospital/ IMIBIC/ Córdoba University. Avda. Menendez Pidal, s/n. 14004-Córdoba, SPAIN,

e-mail: clementinalopezmedina@gmail.com
Tel: +34-616503966;

* These authors contributed equally to this work.

** See section “Acknowledgements”.
ABSTRACT

Objectives: The objectives of this study were: 1) To compare the prevalence of cardiovascular disease and cardiovascular risk factors among different phenotypes of Spondyloarthritis (SpA); 2) To assess the differences in cardiovascular disease and cardiovascular risk factors between two geographical areas, i.e. Northern Europe vs. Mediterranean region; 3) To identify potential predictive factors for high Framingham Risk Score regarding disease features in SpA and geographical area.

Methods: Ancillary analysis of the international, multicentric, observational, cross-sectional ASAS-COMOSPA study. Cardiovascular disease and cardiovascular risk factors were compared depending on SpA phenotype and geographical regions. Potential factors associated with higher cardiovascular risk (i.e. Framingham Risk Score) were determined by a multiple logistic regression.

Results: The most frequent cardiovascular risk factor and cardiovascular disease were smoking (31.2%) and ischemic heart disease (3.2%), respectively. Regarding SpA phenotype, axial SpA patients showed significantly lower prevalence (p<0.05) of hypertension (19.2% vs. 33.8% vs. 26.6% for axial, peripheral and mixed phenotypes, respectively), type 2 diabetes mellitus (4.3% vs. 8.5% vs. 7.4%), dyslipidemia (13.9% vs. 28.4% vs. 15.2%) and ischemic heart disease (2.4% vs. 7.0% vs. 3.2%). Regarding geographical area, a higher frequency of hypertension (34.7% vs. 19.4%), dyslipidemia (19.3% vs. 14.4%), obesity (29.3% vs. 20.7%) and ischemic heart disease (6.2% vs. 1.8%) was observed for Northern Europe vs. Mediterranean Region, respectively.
**Conclusions:** Our results suggest that SpA phenotype and geographical area are associated with the prevalence of cardiovascular risk factors and the cardiovascular risk itself, observed in patients in the ASAS-COMOSPA cohort.

**KEYWORDS:** Spondyloarthritis/ Cardiovascular disease/ Cardiovascular risk factors/ Socio-demographic characteristics.
1. Introduction

Spondyloarthritis (SpA) is a chronic inflammatory disease that presents under different phenotypes depending on the presence of axial or peripheral manifestations [1]. Patients with SpA can present predominantly with axial symptoms (axial SpA) [2], with peripheral arthritis (peripheral SpA) [3] or both (hereafter called mixed SpA). In addition to articular symptoms, many SpA patients exhibit an array of extra-articular manifestations including psoriasis, anterior uveitis and inflammatory bowel disease (IBD) [4]. This phenotypic presentation generated the division into several subtypes, such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), IBD-associated SpA, reactive arthritis and undifferentiated SpA [5].

It has also been reported that patients with SpA present more frequently with comorbidities such as cardiovascular (CV) manifestations, among others [6]. These comorbidities are of particular interest due to their role and their possible involvement in the treatment and prognosis of SpA. An increased mortality has been described in SpA patients compared to the general population, together with a greater risk for CV mortality [7]. Some studies have shown that SpA patients present also an increased risk of cardiovascular disease (CVD) [8,9] compared to the general population. There are several factors that may explain this greater risk, e.g. related to chronic systemic inflammation, to a higher prevalence of classical CV risk factors [10], and to the different treatment modalities depending on the SpA phenotype (i.e. more frequently NSAIDs in axial disease).

There are other factors that could contribute to this high CV risk. Several studies have shown that metabolic syndrome and CVD are common in patients with AS and PsA [11-14]. Nevertheless, the comparison among different SpA phenotypes regarding the prevalence of CV risk has not been reported yet. In addition, several factors such as
environmental, socio-demographic and behavioural (i.e. smoking, age, socioeconomic status, psychological stress, alcohol or unhealthy diet) may also be key CV risk factors in SpA patients. This constellation of factors may be involved in the impairment of the classical CV risk factors, as well as directly in the CV process. More, it has been noted that these factors are associated with increased CV risk [15] in healthy population, with frequencies depending on each country and geographical area [18-20]. In fact, recent epidemiological studies in general population [19,20] show that CVD and mortality rates are higher in Northern European Countries (e.g. UK and Germany) than in some Mediterranean Countries (e.g. Spain and Italy). However, these geographical differences have not been studied in SpA patients. Recent data from the ASAS-COMOSPA study [21] illustrate that the worldwide distribution of CVD is strikingly more frequent in Northern Europe and in USA compared to the rest of the population included in the study.

The ASAS-COMOSPA is an observational, cross-sectional, multicentre and international study, with 22 participating countries from 4 continents (Africa, America, Asia and Europe), and it was performed under the umbrella of ASAS (Assessment in SpondyloArthritis international Society). The ASAS-COMOSPA study had as objectives to evaluate the prevalence of comorbidities and their risk factors in SpA patients and to evaluate the gap between the available recommendations and their implementation in daily practice.

Thus, our aims in the present study were:

- First, to compare CVD and CV risk factors among different SpA phenotypes.
- Secondly, to analyze the differences in SpA characteristics and in CVD/ CV risk factors between two geographical areas (Northern European vs. Mediterranean region).
- Finally, to identify potential factors associated with high Framingham Risk Score (FRS) regarding disease features in SpA and geographical area.
2. Methods

2.1. Study design

This was an ancillary analysis of the ASAS-COMOSPA study, an international, observational, cross-sectional and multicentre study [21]. For the present analysis, only 10 participating countries from two European regions were included: Northern Europe (United Kingdom, Germany, Belgium and Netherlands) and Mediterranean area (Spain, France, Italy, Morocco, Turkey and Egypt). These countries were selected because of dietary similarities (patients from Mediterranean countries consuming the traditional Mediterranean diet, which includes high intake of vegetables, legumes, fruits, nuts and olive oil), genetic, lifestyle and environmental (e.g. hours of sunlight) [22].

2.2. Participants and recruitment

Of the 3984 consecutive adult patients belonging to the paternal study [e.g. at least 18 years old, fulfilling the ASAS criteria (either axial or peripheral) [2,3] and who were able to understand and complete questionnaires included in the original study], we included all participants from the above specified countries selected for the analysis (a total of 2020) [21]; 19 patients were excluded by missing socio-demographic data, resulting in 2001 patients included in this present analysis (1353 participants were from countries of Mediterranean area and 648 from Northern Europe) (Fig. 1). The study was conducted according to guidelines for good clinical practice at the local level. All participants gave written informed consent and underwent a comprehensive medical history, physical examination, and laboratory tests before enrolment. The working protocol was approved by the local ethic committee at each of the intervention centers according to the Helsinki Declaration.
2.3. Data collection

A case report form was used to collect the following data:

A). Demographic and disease characteristics: Demographic characteristics: country of origin, age, gender, body mass index (BMI; calculated as weight in kilograms divided by the square of height in meters. Obese subjects were defined as patients with BMI ≥30 kg/m²) and smoking status as: a) non-smoker [never or past (>3 years)], b) smoker [present or past (≤ 3 years)]. Disease characteristics: disease duration, presence or absence of HLA-B27 antigen, SpA phenotype (defined as only axial/axial and peripheral (mixed)/and only peripheral involvement [3,5]), enthesitis, dactylitis, uveitis, psoriasis, and IBD. Current disease activity was measured by CRP (mg/dL) and ESR (mm/1h) levels, patient and physician global visual analogue scale (VAS; range from 0 to 10), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [23], Ankylosing Spondylitis Disease Activity Score (ASDAS; calculated with the CRP) [24], and the number of swollen and tender joints (44 joint count).

B). CVD and CV risk factors: CVD: history of ischaemic heart disease (IHD) or stroke; risk factors for CVD: hypertension [defined as history of hypertension or antihypertensive therapy or blood pressure (BP) > 140/90 mm Hg (>130/80 mm Hg in case of history of diabetes or renal insufficiency) at the study visit], type 2 diabetes mellitus (T2DM) [defined as history of diabetes or glycaemia >7.0 mmol/L], dyslipidemia (defined as history of hypercholesterolaemia or cholesterol-lowering therapy or an low-density lipoprotein (LDL) cholesterol above target according to the French recommendations [25], chronic renal failure (CRF) [defined as kidney damage or glomerular filtration rate (GFR) <60 mL/min/1.73 m² for 3 months or more], and family history of myocardial infarction (MI). Furthermore, the Framingham Risk Score (FRS) [26], was used to estimate the 10-year risk for a CV event of an individual [range
from <5 % (low risk) to ≥15% (high risk)]. All these variables were collected during a one-to-one study visit for the parent study including the review of the medical charts.

2.4. Statistical analysis

All data presented in the Figure and Tables are expressed as mean and Standard Deviation (SD) for continuous variables, and as number and/or percentage of patients for categorical variables. Chi-square test (categorical variables) and Independent-Samples t test (continuous variables) were used to evaluate the association between CV risk factors and SpA phenotype, and to compare the prevalence of SpA clinical characteristics and CV risk in Northern European vs. Mediterranean countries.

A multiple logistic regression was performed to assess the variables potentially associated with high FRS (FRS≥15) by including in the model the most important phenotypes and disease activity covariates. Those covariates which reflect CV risk were excluded from the model, with the aim to avoid the presence of similar components on both sides of the equation. Interactions, confounding factors and collinearity were tested, and all comparisons were bilateral considering p≤0.05 as a significant result.

SPSS 17.0 for Windows was used for the statistical analysis.

2.5. Funding source

The ASAS-COMOSPA parent study was conducted thanks to an unrestricted grant from Abbvie, Pfizer and UCB. This ancillary study has not any funding source.
3. Results

Demographics and disease characteristics of the 2001 patients included are summarized in Table 1. Participants were predominantly males (1202, 60.1%), had an average age of 46.1 ± 13.3 years and a disease duration of 9.5 ± 10.4 years. A half of patients exhibited mixed involvement (50.1%), whereas 39.8% and 10.1% of patients presented only axial and only peripheral phenotype, respectively.

In the entire population, the most prevalent CV risk factor was smoking (n=625, 31.2%), followed by hypertension (n=488, 24.4%) and obesity (n=468, 23.4%). Prevalence of T2DM, dyslipidemia, family history of MI and CRF were 6.2%, 15.9%, 18.0% and 2.2%, respectively. Regarding CVD, the estimated prevalence for IHD in our study was 3.2% whereas for stroke was 1.6% (Fig. 2).

The analysis of the association between CV risk and SpA phenotype is shown in Table 2. Several CV risk factors were noted to be less frequent in axial SpA patients compared to patients with peripheral and/or mixed involvement. Particularly, axial SpA patients exhibited lower prevalence of hypertension (19.2% vs. 33.8% vs. 26.6%, for axial, peripheral and mixed phenotypes, respectively) (p<0.001) and T2DM (4.3% vs. 8.5% vs. 7.4%, for axial, peripheral and mixed phenotypes, respectively) (p=0.010) than peripheral and mixed SpA patients. Obesity (19.0% vs. 24.9% vs. 26.8%, for axial, peripheral and mixed phenotypes, respectively) (p=0.001) and family history of MI (15.3% vs. 15.6% vs. 21.1%, for axial, peripheral and mixed phenotypes, respectively) (p=0.007) were less frequently detected in axial SpA compared to mixed SpA. Furthermore, dyslipidemia was less prevalent (13.9% vs. 28.4% vs. 15.2%, for axial, peripheral and mixed phenotypes, respectively), and FRS was lower (8.0 vs. 9.4 vs. 8.7, for axial, peripheral and mixed phenotypes, respectively) in axial and mixed SpA patients as compared to peripheral SpA (p<0.001). Regarding tobacco, a higher
prevalence of smoking was observed in axial SpA patients compared to peripheral and mixed SpA patients (38.1% vs 27.4% vs 26.5%, for axial, peripheral and mixed phenotypes, respectively) (p<0.001). Concerning CVD, there were no significant differences for stroke among SpA phenotypes; however, IHD was less frequent in axial and mixed SpA patients compared to peripheral SpA patients (2.4% vs 7.0% vs 3.2%, for axial, peripheral and mixed phenotypes, respectively) (p<0.05).

SpA clinical characteristics and the prevalence of CV risk and CVD in patients from Northern European vs. Mediterranean countries was compared (Table 3). Geographically, 1353 patients (67.6%) belonged to Mediterranean area countries and 648 (32.4%) to Northern European countries, with an average disease duration of 7.9 ± 12.0 and 12.8 ± 12.3 years, respectively. A higher mean age (49.9±13.5 vs 44.28±12.7 years, p<0.001) and longer disease duration (12.8±12.3 vs 7.9±12.0 years, p<0.001), was noted in north Europeans. These patients also have significantly higher frequency of HLA-B27 antigen (72.6% vs 56.6%, p<0.001), dactylitis (18.7% vs 13.2%, p<0.001), uveitis (26.4% vs 17.4%, p<0.001), psoriasis (35.8% vs 20.3%, p<0.001) and IBD (11.1% vs 7.0%, p=0.002). Regarding CV risk, higher prevalence of hypertension (34.7% vs 19.4%, p<0.001), dyslipidemia (19.3% vs 14.4%, p=0.005), obesity (29.3% vs 20.7%, p<0.001) and CRF (3.9% vs 1.5%, p=0.001) was observed in patients from countries of Northern European region vs. Mediterranean region. Further, a higher prevalence of IHD (6.2% vs 1.8%, p<0.001), was detected in patients from Northern European vs. Mediterranean countries. Detailed prevalence for CVD and CV risk factors per sex, age interval and country are summarised in an additional file [Appendix A, Tables S1-S10; See the supplementary material associated with this article online].

Finally, a multiple logistic regression model was used to identify potential predictors of high FRS (Table 4). A higher FRS was present in SpA patients from Northern
European vs. Mediterranean region (OR 1.69; p<0.001). Furthermore, elevated FRS was observed in patients with a longer disease duration (OR 1.09; p<0.001), peripheral involvement (OR 1.62; p=0.025), psoriasis (OR 1.83; p<0.001), presence of tender joints (OR 1.03; p=0.004) and elevated ESR levels (OR 1.01; p=0.040).
4. Discussion

To our knowledge, this is the first study that has assessed the prevalence of CVD and its classical risk factors in patients with different SpA phenotypes together with the influence of the geographical area (Northern Europe vs. Mediterranean) in the prevalence of CV risk and SpA clinical characteristics.

Several studies have suggested an increased risk of hypertension, T2DM, obesity and dyslipemia in the two most common subtypes of SpA, PsA [11,13,27] and AS [10,11,28], compared to the general population. However, studies evaluating the CV risk profile between both diseases have provided contradictory results [11,14,29], showing a similar or lower prevalence of CV risk in AS than PsA patients. The observed discrepancies may be due to the fact that these studies do not compared all clinical phenotypes present in SpA. The present analysis, conducted in the ASAS-COMOSPA database, is the first one that took into account the phenotypes of the disease. Our results demonstrated that axial SpA patients exhibited a lower prevalence of traditional CV risk factors than patients with peripheral and/or mixed phenotypes, and this could be associated to a lower development of CV events. Consistent with our results, previous data showed that predominantly axial SpA is related with a lower frequency of hypertension, dyslipidemia, T2DM and obesity [14,30] than PsA (a mainly peripheral disease). However, an increased prevalence of family history of MI was observed in patients with axial SpA, an independent risk factor that may contribute to a higher prevalence of CVD [30]. Finally, a higher prevalence of smoking was observed in patients with axial phenotype than in those with peripheral and mixed phenotype, as previously reported in AS patients [14,29].

Regarding CV comorbidities, previous studies have demonstrated an increased risk of CV mortality in AS and PsA patients [31], with a prevalence of CV events similar for
both diseases [11,29]. However, as mentioned above, these studies did not consider the clinical phenotype of the disease. Our present study is the first one, to our knowledge, which showed that IHD has a lower prevalence in axial SpA patients than those with peripheral phenotype. Moreover, the decreased prevalence of CVD in axial SpA is consistent with our results demonstrating that these patients exhibit less classical CV risk factors (i.e. hypertension, obesity, T2DM, dyslipidemia and family history of MI) than peripheral and/or mixed SpA patients.

The reason for the reduced prevalence of CVD and its traditional risk factors in axial SpA patients could be due to the low disease activity in these patients, which results in a decrease of pro-inflammatory state and, consequently, in a reduction in classical CV risk factors (i.e. dyslipidemia, T2DM, obesity). Nevertheless, in our present study, there are non-significant differences in disease activity between axial and peripheral phenotypes; although, mixed SpA patients exhibited higher levels of disease activity markers than axial and peripheral SpA patients. An additional file shows this in more detail (Appendix A, Table S11). Our findings are indicative of an inflammatory status at the recruitment moment and only a history of low activity during disease progression might explain the reduced CV events observed in axial SpA patients. Additional factors should be taken into account for the difference in CV risk between phenotypes. Perhaps one of the causes of the increased prevalence of vascular risk in peripheral SpA patient is the physical inactivity as a result of progressive joint damage. On the same note, PsA patients showed low levels of physical exercise [32] and in rheumatoid arthritis (a predominantly peripheral form) an association of physical inactivity with increased CV risk [33] has been demonstrated. Likewise, a higher prevalence of metabolic syndrome, an independent predictor of CV events, has been noted in patients with PsA, but not AS, compared to the general population [14].
The comparison of the two population groups suggested that SpA patients from the
two geographical regions displayed differences in phenotype, CV comorbidities and in
classical CV risk factors. Specifically, SpA patients from Northern European countries
showed a lower prevalence of axial involvement, as well as a higher mean age, longer
disease duration, an elevated prevalence of HLA-B27 antigen and extra-articular
manifestations than countries from Mediterranean region. In relation to CV risk, SpA
patients from Northern European area showed a higher prevalence of traditional CV risk
factors (i.e. obesity, hypertension, dyslipidemia, and CRF) and CV comorbidities (i.e.
IHD) than those from Mediterranean countries. The increased CV events in Northern
European region could be explained by the older age of the patients and longer mean
disease duration, both factors related to the development of CVD [34,35]. Likewise, an
HLA-B27-associated cardiac syndrome consisting of aortic insufficiency and atrial
ventricular block has been described [36], demonstrating the implication of this antigen
in CV pathogenesis. Nevertheless, the higher prevalence of peripheral involvement
observed in this geographical area might also contribute to increased development of
CV risk factors observed in these patients (Appendix A, Table S12).

The prevalence of CV risk profile was different than what has been reported in
healthy individuals from each geographical area. Specifically, in Northern Europe the
prevalence of obesity was estimated at 11.8% in healthy individual (reference data from
Netherlands) [37,38] whereas in our SpA patients it was 29.30%. However, global
prevalence of dyslipidemia, hypertension and T2DM was similar in healthy individuals
(23.2%, 31.4% and 7.9% respectively) and SpA patients (19.3%, 34.7% and 6.0%
respectively). Regarding countries from Mediterranean region, we noted that the
estimated prevalence of hypertension, dyslipidemia and T2DM was 42.6 %, 49.5 % and
13.6 % in healthy individual (reference data from Spain) [39,40] and 19.4 %, 14.4 %
and 6.4 % in our SpA patients. In relation to obesity, we observed that the global prevalence was estimated at 29.7 % in healthy individuals and 20.7 % in SpA patients. Thus, our data suggest that disease phenotype may be involved in the development of CV comorbidities in SpA patients.

This study presents some limitations. First, the study was performed in 2001 of the 3984 patients who form the COMOSPA database, which can hamper the external validity of the study. Secondly, the prevalence of CVD might have been underestimated as a result of the inability of patients to participate or even died at a premature age, preventing them to collaborate in the study. Finally, the prevalence of CV comorbidities in these patients was variable across countries. This finding can be explained by the socioeconomic differences, which has an effect on health systems, and differences in diet, genetic and environment; however, it is possible that this may be also influenced by the selection type used in each country.

Overall, our results seem to indicate that SpA phenotype and socio-demographic characteristics are associated with the CV risk observed in the two geographical areas. A better knowledge of the association between SpA and CV comorbidities is useful for the development of a comprehensive and integrated intervention in the prevention of CVD, for minimizing the impact of the CV risk, and for improving patients’ long-term outcome.

Disclosure of interests. The authors declare that they have no interest related for this work.

Acknowledgements. National coordinators of ASAS-COMOSPA from the participating countries in this study: BRAUN, Jurgen (Germany), HAJJAJ-HASSOUNI, Najia (Morocco), KAMAL EL-ZORKANY, Bassel (Egypt), MONTECUCCO, Carlo-

**Appendix A. Supplementary data**

Supplementary data (Table S1-S12) associated with this article can be found in the online version at ...
References


ASAS-endorsed disease activity score in patients with ankylosing spondylitis.


[28] Chen HH, Yeh SY, Chen HY, Lin CL, Sung FC, Kao CH. Ankylosing spondylitis and other inflammatory spondyloarthritis increase the risk of developing type 2 diabetes in an Asian population. Rheumatol Int. 2014;34(2):265-270.


Figure legend section

Figure 1. Distribution of the 2001 patients selected from the parent COMOSPA study.

Figure 2. Prevalence of Cardiovascular risk factors and Cardiovascular Disease in the entire population.

T2DM: type 2 diabetes mellitus. CRF: Chronic renal failure. MI: myocardial infarction
Table 1. Demographic data and disease characteristics of the 2001 patients from the ASAS-COMOSPA study.

<table>
<thead>
<tr>
<th></th>
<th>Global results (%)</th>
<th>Axial involvement (%)</th>
<th>Axial and peripheral involvement (%)</th>
<th>Peripheral involvement (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>2001</td>
<td>797 (39.8)</td>
<td>1003 (50.1)</td>
<td>201 (10.1)</td>
</tr>
<tr>
<td>Age (years), Mean (SD)</td>
<td>46.1 (13.3)</td>
<td>43.9 (12.6)</td>
<td>46.5 (13.3)</td>
<td>53.1 (13.1)</td>
</tr>
<tr>
<td>Gender (males)</td>
<td>1202 (60.1)</td>
<td>536 (67.3)</td>
<td>543 (54.1)</td>
<td>123 (61.2)</td>
</tr>
<tr>
<td>Disease duration (years), Mean (SD)</td>
<td>9.5 (10.4)</td>
<td>9.2 (10.5)</td>
<td>10.0 (10.7)</td>
<td>8.3 (8.1)</td>
</tr>
<tr>
<td>HLA-B27</td>
<td>967 (62.67)</td>
<td>471 (59.2)</td>
<td>454 (45.7)</td>
<td>42 (21.0)</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>805 (40.2)</td>
<td>208 (26.1)</td>
<td>526 (52.4)</td>
<td>71 (35.3)</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>299 (14.9)</td>
<td>0 (0)</td>
<td>212 (21.1)</td>
<td>87 (43.3)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>406 (20.3)</td>
<td>164 (20.6)</td>
<td>224 (22.3)</td>
<td>18 (9.0)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>506 (25.3)</td>
<td>81 (10.2)</td>
<td>285 (28.4)</td>
<td>140 (69.7)</td>
</tr>
<tr>
<td>IBD</td>
<td>167 (8.3)</td>
<td>56 (7.0)</td>
<td>106 (10.6)</td>
<td>5 (2.5)</td>
</tr>
</tbody>
</table>

All results are presented as mean and Standard Deviation (SD), and as percentages for continuous and categorical variables, respectively.

Percentages indicate number of patients with the covariate from the total number of patients in each category.

HLA: Human leukocyte antigen; IBD: Inflammatory Bowel Disease.

1HLA-B27: percentage from the total of available data (n=1543).
All results are presented as percentages for categorical variables, and as mean and Standard Deviation (SD) for continuous variables. Percentages indicate number of patients with the covariate from the total number of patients in each disease clinical form.

1 Calculated using ANOVA for the covariate FRS with Post-hoc analysis using Sidak test, and a chi-square test for the rest of covariates.

a significant differences (p≤0.05) regarding Axial involvement.

b significant differences (p≤0.05) regarding Axial and Peripheral involvement.
CRF: Chronic Renal Failure; IHD: Ischemic heart disease; FRS: Framingham Risk Score. MI: Myocardial infarction. T2DM: Type 2 diabetes mellitus.
Table 3. Comparison of the prevalence of disease characteristics, CV risk factors and CVD in Northern European countries vs. Mediterranean countries.

<table>
<thead>
<tr>
<th>Global results</th>
<th>Mediterranean countries</th>
<th>Northern European countries</th>
<th>OR (95% CI)</th>
<th>p-value(^1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>n=2001 (%)</td>
<td>n=1353 (%)</td>
<td>n=648 (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years), Mean (SD)</td>
<td>46.1 (13.3)</td>
<td>44.28 (12.7)</td>
<td>49.95 (13.5)</td>
<td>1.03 (1.02-1.04)</td>
</tr>
<tr>
<td>Sex (male)</td>
<td>1202 (60.1)</td>
<td>804 (59.4)</td>
<td>398 (61.4)</td>
<td>1.09 (0.90-1.32)</td>
</tr>
<tr>
<td>Disease d (years), Mean (SD)</td>
<td>9.5 (10.4)</td>
<td>7.9 (12.0)</td>
<td>12.8 (12.3)</td>
<td>1.04 (1.03-1.05)</td>
</tr>
<tr>
<td>HLA- B27(^2)</td>
<td>967 (62.67)</td>
<td>604 (40.4)</td>
<td>363 (56.6)</td>
<td>2.46 (1.93-3.14)</td>
</tr>
<tr>
<td>Clinical form</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Axial (ref.)</td>
<td>797 (39.8)</td>
<td>585 (43.2)</td>
<td>212 (32.7)</td>
<td>Reference</td>
</tr>
<tr>
<td>- Axial and peripheral</td>
<td>1003 (50.1)</td>
<td>671 (49.6)</td>
<td>332 (51.2)</td>
<td>1.36 (1.11-1.67)</td>
</tr>
<tr>
<td>- Peripheral</td>
<td>201 (10.1)</td>
<td>97 (7.17)</td>
<td>104 (16.05)</td>
<td>2.96 (2.15-4.07)</td>
</tr>
<tr>
<td>Enthesitis</td>
<td>805 (14.9)</td>
<td>547 (40.4)</td>
<td>258 (39.8)</td>
<td>0.97 (0.80-1.18)</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>299 (40.2)</td>
<td>178 (13.2)</td>
<td>121 (18.7)</td>
<td>1.52 (1.18-1.95)</td>
</tr>
<tr>
<td>Uveitis</td>
<td>406 (20.3)</td>
<td>235 (17.4)</td>
<td>171 (26.4)</td>
<td>1.71 (1.37-2.14)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>506 (23.3)</td>
<td>274 (20.3)</td>
<td>232 (35.8)</td>
<td>2.19 (1.78-2.70)</td>
</tr>
<tr>
<td>IBD</td>
<td>167 (8.3)</td>
<td>95 (7.0)</td>
<td>72 (11.1)</td>
<td>1.65 (1.2-2.28)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>488 (24.4)</td>
<td>263 (19.4)</td>
<td>255 (34.7)</td>
<td>2.20 (1.78-2.72)</td>
</tr>
<tr>
<td>T2DM</td>
<td>125 (6.2)</td>
<td>86 (6.4)</td>
<td>39 (6.0)</td>
<td>0.94 (0.64-1.39)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>320 (15.9)</td>
<td>195 (14.4)</td>
<td>125 (19.3)</td>
<td>1.42 (1.11-1.81)</td>
</tr>
<tr>
<td>Obesity</td>
<td>468 (23.4)</td>
<td>280 (20.7)</td>
<td>188 (29.3)</td>
<td>1.59 (1.28-1.96)</td>
</tr>
<tr>
<td>CRF</td>
<td>45 (2.2)</td>
<td>20 (1.5)</td>
<td>25 (3.9)</td>
<td>2.67 (1.47-4.85)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>625 (31.2)</td>
<td>406 (30.0)</td>
<td>219 (33.8)</td>
<td>1.19 (0.97-1.45)</td>
</tr>
<tr>
<td>Family history of MI</td>
<td>359 (18.0)</td>
<td>232 (17.1)</td>
<td>127 (19.6)</td>
<td>1.16 (0.92-1.48)</td>
</tr>
<tr>
<td>IHD</td>
<td>65 (3.2)</td>
<td>25 (1.8)</td>
<td>40 (6.2)</td>
<td>3.49 (2.10-5.81)</td>
</tr>
<tr>
<td>Stroke</td>
<td>33 (1.6)</td>
<td>17 (1.3)</td>
<td>16 (2.5)</td>
<td>1.99 (0.99-3.96)</td>
</tr>
<tr>
<td>FRS, Mean (SD)</td>
<td>8.8 (8.6)</td>
<td>7.49 (7.8)</td>
<td>11.42 (9.6)</td>
<td>1.05 (1.04-1.06)</td>
</tr>
</tbody>
</table>
All results are presented as mean and Standard Deviation (SD), and number of patients (%) for continuous and categorical variables, respectively. Percentages indicate number of patients with the covariate from the total number of patients in each category.

1 Calculated using a univariate logistic regression. Mediterranean countries were used as the reference category. The OR represents Northern European countries vs. Mediterranean countries.

2 Number of HLA-B27 positive patients from the total of available data (n=1532).

Disease d: disease duration. HLA: Human leukocyte antigen; CI: Confidence interval; CRF: Chronic Renal Failure; FRS: Framingham Risk score; IBD: Inflammatory bowel disease; IHD: Ischemic heart disease; MI: Myocardial Infarction; OR: Odds Ratio; SD: Standard deviation; T2DM: Type 2 diabetes mellitus. Ref.: Reference.
Table 4. Identification of potential predictors of high Framingham index score\(^1\).

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR (95% CI)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>North Europe (ref. Mediterranean patients)</td>
<td>1.68 (1.28 – 2.21)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>1.09 (1.08 – 1.11)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Clinical form:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mixed involvement (ref. axial)</td>
<td>1.02 (0.76 – 1.37)</td>
<td>0.877</td>
</tr>
<tr>
<td>- Peripheral involvement (ref. axial)</td>
<td>1.85 (1.25 – 2.75)</td>
<td>0.002</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>1.99 (1.47 – 2.69)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Dactylitis</td>
<td>0.65 (0.45 – 0.95)</td>
<td>0.024</td>
</tr>
<tr>
<td>Number of tender joints</td>
<td>1.03 (1.01 – 1.05)</td>
<td>0.003</td>
</tr>
<tr>
<td>ESR</td>
<td>1.01 (1.00 – 1.01)</td>
<td>0.042</td>
</tr>
</tbody>
</table>

Hosmer-Lemeshow test: χ\(^2\) square = 8.916, p=0.349

\(^1\) Calculated using a multiple logistic regression. Primary outcome: Framingham risk score ≥15.

Variables included in the model: Disease duration, geographical area, HLA-B27, clinical form, dactylitis, enthesitis, uveitis, psoriasis, inflammatory bowel disease, number of tender joints, number of swollen joints, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), ASDAS-CPR (Ankylosing Spondylitis Disease Activity Score-CRP), CPR (C Reactive Protein), ESR (Erythrocyte Sedimentation Rate) and PGVAS (Patient Global Visual Analogue Scale).

Ref.: Reference.
Fig. 1. Distribution of the 2001 patients selected from the parent COMOSPA study.

3984 patients from the parent study

1964 patients from the excluded countries

2020 patients from the 10 selected countries

19 patients excluded because of socio-demographic missing data

2001 patients included in the final analysis

648 patients from Northern Europe

1353 patients from Mediterranean countries
Fig. 2. Prevalence of Cardiovascular risk factors and Cardiovascular Disease in the entire population.